QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Jul 23, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how a blood test called the QuantiFERON-CMV test can help predict the reactivation of Cytomegalovirus (CMV) in patients with Ulcerative Colitis (UC). CMV can make UC worse, leading to more severe symptoms and making treatment less effective. The goal is to see if this non-invasive blood test can provide useful information about a patient's immune response to CMV, which might help doctors manage the condition better.

To participate in the trial, candidates must be hospitalized due to a flare-up of Ulcerative Colitis and have a positive test for past CMV infection. Participants will need to give their consent and agree to have their blood tested. This trial is currently looking for patients aged between 65 and 74, and it is open to all genders. It's important to know that some individuals, like those who have had certain surgeries or cannot understand the study, may not be eligible. Overall, this study aims to find a simpler way to monitor CMV that could improve care for those dealing with Ulcerative Colitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with seropositive for CytoMegaloVirus (CMV) (IgG+)
• • Patient requiring hospitalization for flare of Ulcerative Colitis (UC) with Mayo score \> 5 and an endoscopic subscore ≥ 2
• • Social security affiliation
• • Signed informed consent
• Exclusion Criteria:
• • Wardship patient and curatorial patient
• • Patient unable to understand or sign the protocol
• • Colectomy total or partial